Psychedelic Biotech Company Cybin Partners with Greenbrook to Develop Innovative Depression Treatment
Cybin CEO says agreement “serves as a major step toward establishing a national distribution network for future psychedelic therapies.”
Cybin CEO says agreement “serves as a major step toward establishing a national distribution network for future psychedelic therapies.”
Alcohol, methamphetamine and cocaine have been linked to increased aggression in men, but psychedelics appear to have opposite effect.
This week in psychedelic business news: Companies embrace the psychedelic aspects of VR, Braxia trains therapists in psychedelic best practices, and Allied gears up to provide its psychedelic formulation to PTSD patients.
Havn Life Sciences is expanding its psilocybin cultivation in Jamaica where the psychedelic mushrooms are legal to grow.
The Bob Marley-inspired line of psychedelic and functional mushrooms, Marley One, has officially launched through partner Silo Wellness.
The University of Alabama at Birmingham is the latest to announce it will begin research into psychedelics.
Mydecine Innovations Group says it has found 40 new compounds in at least 25 types of mushrooms with psychedelic and potentially therapeutic properties.
Is synthetic psilocybin as effective as the real thing? A new study looks at the risks and benefits of taking this lab-made psychedelic.
New research into psychedelics shows psilocybin may help amputees suffering from pain associated with phantom limb syndrome.
A new investigation into treatment for migraines spotlights the psychedelic psilocybin mushroom as a promising prospect.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.